Skip to main content
KALA
NASDAQ Life Sciences

KALA BIO Amends $350M Shelf Registration to Reflect 1-for-50 Reverse Stock Split

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$2.58
Mkt Cap
$48.891M
52W Low
$2.03
52W High
$1,030
52W Position info
27% above low
Off High info
100% below high
Rel. Volume info
2.4× avg
Market data snapshot near publication time

KALA sits 27% above its 52-week low of $2.03 on elevated volume (2.4× avg).

Summary

KALA BIO filed an amendment to its $350 million universal shelf registration, updating it to reflect the recent 1-for-50 reverse stock split and enabling future capital raises under the new share structure.


Key Events · Financing and Capital Events · KALA

  • Shelf Registration Updated

    The company amended its universal shelf registration statement for up to $350 million in various securities. This updates the existing shelf, originally filed on May 7, 2026, to align with the company's new capital structure.

  • Reflects Reverse Stock Split

    The amendment formally incorporates the 1-for-50 reverse stock split, effective May 8, 2026, which significantly reduced the number of outstanding shares from 929,491,578 to 18,589,787.

  • Significant Potential Dilution

    The $350 million shelf represents a substantial amount relative to the company's market capitalization, indicating a high potential for dilution if the securities are issued.

  • Enables Future Capital Raises

    This amendment is a critical step to allow KALA BIO to access capital under the existing shelf registration, which is important given the company's ongoing financial challenges and business transition.


Analysis · KALA · Life Sciences

This amendment updates the company's existing $350 million universal shelf registration to reflect the recent 1-for-50 reverse stock split. While not a new capital raise, this filing is a necessary administrative step to enable future offerings under the shelf. The potential for $350 million in new securities represents a substantial amount relative to the company's current market capitalization, indicating significant potential dilution for existing shareholders if fully utilized. This capital access is critical for KALA BIO, which has disclosed going concern doubts and is transitioning its business model.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KALA was trading at $2.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.9M. The 52-week trading range was $2.03 to $1,030.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KALA - Latest Insights

KALA
Nov 12, 2026, 8:00 AM EST
Source: TMX Newsfile
Importance Score:
7
Price at Filing: $0.149
Real-time Price: $0.1398 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Nov 09, 2026, 8:00 AM EST
Source: TMX Newsfile
Importance Score:
7
Price at Filing: $0.1568
Real-time Price: $0.1398 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Sep 29, 2026, 7:30 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.474
Real-time Price: $0.1398 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Sep 24, 2026, 4:10 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.5288
Real-time Price: $0.1398 info
Change: Reverse Stock Split info
Market Cap: $2.684M info
KALA
Sep 11, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $0.1398 info
Change: Reverse Stock Split info
Market Cap: $2.684M info